Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several milk-excretion claims are unsupported by the provided label excerpts, which state only that it is not known whether atorvastatin is excreted into human milk and advise against breastfeeding if treatment is required. Claims about patent expiration, generics availability, and bioavailability/formulation differences are not addressed in the supplied labeling and are therefore unsupported.
Category Scores
Accurate Statements
Atorvastatin's patent has expired in the US.
Not supported or mentioned in the provided FDA label excerpts (regulatory/market exclusivity not covered).
Generic versions of atorvastatin are available.
Not supported or mentioned in the provided FDA label excerpts (generic availability not covered).
Unsupported Statements
Atorvastatin is present in human milk at very low concentrations.
The provided label excerpt says it is not known whether atorvastatin is excreted into human milk; it does not state presence or concentration.
In a study, atorvastatin concentrations were 0.0004-0.0011% of the maternal dose in the infant's plasma.
No such numeric infant plasma fraction is provided in the supplied label excerpts.
Atorvastatin is secreted into breast milk.
The provided label excerpt states it is not known whether atorvastatin is excreted into human milk.
In a study, the infant dose was approximately 0.004-0.011% of the maternal dose.
No such study result or percentage appears in the supplied label excerpts.
A review found atorvastatin to be one of the statins with the lowest passage into breast milk.
The supplied label excerpts do not include comparative review findings about passage into breast milk.
Generic atorvastatin may have varying formulations and bioavailability compared to branded Lipitor.
The supplied label excerpts do not address generic formulation/bioavailability differences.
Contradictions
High
AI Statement
Atorvastatin is secreted into breast milk.
Label Reference
Section 4 (Contraindications) / Nursing Mothers excerpt: “It is not known whether atorvastatin is excreted into human milk...”
Important Omissions
The label guidance for nursing: women requiring LIPITOR treatment should be advised not to nurse their infants.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The response asserts that atorvastatin is present/secreted into breast milk and provides numeric exposure estimates, while the provided label excerpt indicates excretion into human milk is not known and advises against breastfeeding when treatment is required. This could materially mislead about nursing safety relative to the provided labeling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Misstates nursing-mothers milk excretion status and omits the label’s breastfeeding restriction; other non-label claims about studies, patent status, and generic formulation/bioavailability are unsupported by the provided labeling excerpts.
Suggested Improvement
Replace milk-excretion/exposure assertions with the label statement (“It is not known whether atorvastatin is excreted into human milk… women requiring LIPITOR treatment should not breastfeed their infants”) and remove or avoid unsupported numeric study results and non-label market/generic statements.